S&P 500   5,133.93 (-0.06%)
DOW   39,002.09 (-0.22%)
QQQ   444.71 (-0.20%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
S&P 500   5,133.93 (-0.06%)
DOW   39,002.09 (-0.22%)
QQQ   444.71 (-0.20%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
S&P 500   5,133.93 (-0.06%)
DOW   39,002.09 (-0.22%)
QQQ   444.71 (-0.20%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
S&P 500   5,133.93 (-0.06%)
DOW   39,002.09 (-0.22%)
QQQ   444.71 (-0.20%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
NASDAQ:XNCR

Xencor (XNCR) Stock Price, News & Analysis

$23.71
-0.11 (-0.46%)
(As of 11:39 AM ET)
Today's Range
$23.27
$24.14
50-Day Range
$18.65
$26.52
52-Week Range
$16.49
$32.00
Volume
89,526 shs
Average Volume
719,374 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.71

Xencor MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
50.6% Upside
$35.71 Price Target
Short Interest
Bearish
10.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.01mentions of Xencor in the last 14 days
Based on 42 Articles This Week
Insider Trading
Selling Shares
$1.99 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.29) to ($3.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.77 out of 5 stars

Medical Sector

253rd out of 948 stocks

Pharmaceutical Preparations Industry

116th out of 440 stocks


XNCR stock logo

About Xencor Stock (NASDAQ:XNCR)

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

XNCR Stock Price History

XNCR Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Xencor’s Strategic Focus and Pipeline Progress Affirm Buy Rating
Xencor (NASDAQ:XNCR) Rating Reiterated by Piper Sandler
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Xencor (NASDAQ:XNCR) Downgraded by StockNews.com
Xencor Inc XNCR
Xencor Full Year 2023 Earnings: Misses Expectations
Xencor (NASDAQ:XNCR) Shares Gap Down on Disappointing Earnings
Xencor Q4 2023 Earnings Preview
Xencor to Present at Upcoming Investor Conferences
Unveiling 4 Analyst Insights On Xencor
Xencor (XNCR) Gets a Buy from TD Cowen
Xencor: Q4 Earnings Snapshot
Xencor earnings preview: what Wall Street is expecting
6XNCR : Earnings Preview: Xencor
Xencor (XNCR) to Release Earnings on Tuesday
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by StockNews.com
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/04/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XNCR
Employees
281
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.71
High Stock Price Target
$50.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+49.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-55,180,000.00
Pretax Margin
-71.55%

Debt

Sales & Book Value

Annual Sales
$168.34 million
Book Value
$10.99 per share

Miscellaneous

Free Float
57,850,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
0.76
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Bassil I. Dahiyat Ph.D. (Age 54)
    Co-Founder, CEO, President & Director
    Comp: $1.08M
  • Mr. John J. Kuch (Age 65)
    Senior VP & CFO
    Comp: $660.75k
  • Dr. John R. Desjarlais Ph.D. (Age 60)
    Executive VP of Research & Chief Scientific Officer
    Comp: $711.45k
  • Ms. Celia E. Eckert J.D. (Age 51)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $646.25k
  • Dr. Nancy Valente M.D. (Age 65)
    Executive VP & Chief Development Officer
    Comp: $28.16k
  • Mr. Charles Liles
    Associate Director and Head of Corporate Communications & Investor Relations
  • Ms. Jennifer Sandoz
    Vice President of Human Resources
  • Dr. Jeremy Grunstein Ph.D.
    Senior Vice President of Business Development
  • Mr. Kirk Rosemark RAC (Age 59)
    Senior Vice President of Regulatory Affairs & Quality Assurance
  • Mr. Eric P. Kowack
    Senior Vice President of Program Leadership & Alliance Management














XNCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price target for 2024?

8 equities research analysts have issued 12-month price targets for Xencor's shares. Their XNCR share price targets range from $24.00 to $50.00. On average, they predict the company's share price to reach $35.71 in the next year. This suggests a possible upside of 50.6% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2024?

Xencor's stock was trading at $21.23 at the beginning of the year. Since then, XNCR shares have increased by 11.7% and is now trading at $23.71.
View the best growth stocks for 2024 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.36 by $0.67. The biopharmaceutical company earned $44.70 million during the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative net margin of 74.90% and a negative trailing twelve-month return on equity of 18.67%. The company's quarterly revenue was up 106.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.20) EPS.

What ETFs hold Xencor's stock?
What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (14.62%), Vanguard Group Inc. (11.12%), Price T Rowe Associates Inc. MD (5.72%), Price T Rowe Associates Inc. MD (5.72%), Armistice Capital LLC (2.46%) and Dimensional Fund Advisors LP (2.10%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch and John R Desjarlais.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XNCR) was last updated on 3/4/2024 by MarketBeat.com Staff